deltatrials
Completed PHASE3 NCT00022516

Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer

Low-dose Cytotoxics as Anti-angiogenesis Treatment Following Adjuvant Induction Chemotherapy for Patients With ER-negative and PgR-negative Breast Cancer

Sponsor: ETOP IBCSG Partners Foundation

Conditions Breast Cancer
Interventions Cyclophosphamide Methotrexate
Updated 8 times since 2017 Last updated: Aug 5, 2016 Started: Nov 30, 2000 Primary completion: Jan 31, 2015 Completion: Aug 31, 2016

A PHASE3 clinical study on Breast Cancer, this trial is completed. The trial is conducted by ETOP IBCSG Partners Foundation and has accumulated 8 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Oct 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Dec 2021 — Oct 2022 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE3

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  3. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Nov 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ETOP IBCSG Partners Foundation
Data source: ETOP IBCSG Partners Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland, Adelaide, Australia, Bellinzona, Switzerland, Bergamo, Italy, Bern, Switzerland, Biella, Italy, Box Hill, Australia, Budapest, Hungary, Carpi, Italy, Christchurch, Australia and 22 more location s